Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1615256 | 0.91 | TSHR (0.36) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL18233786 | 0.89 | TSHR (0.41) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL10301168 | 0.89 | TSHR (0.41) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL1104611 | 0.89 | — | — | |
| SCHEMBL804728 | 0.87 | TSHR (0.38) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL14700556 | 0.87 | TSHR (0.33) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL804365 | 0.85 | MEN1 (0.38) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL1636800 | 0.85 | TSHR (0.32) | TSHR | |
| SCHEMBL16260481 | 0.83 | TSHR (0.31) | TSHR | |
| SCHEMBL13251278 | 0.83 | TSHR (0.35) | TSHRMEN1THRBHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399524-B2 | Acyl acidic amino acid ester | AJINOMOTO CO., INC. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120071570-A1 | NOVEL ACYL ACIDIC AMINO ACID ESTER | AJINOMOTO CO., INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7884171-B2 | Implantable medical device; prosthetics; surface behavior of polymers is modified by amphipathic surface-modifying endgroups | DSM IP ASSETS B.V. (NL) | 2011-02-08 | — | — | US | disclosed |
| US-20100113711-A1 | CONTROL OF POLYMER SURFACE MOLECULAR ARCHITECTURE VIA AMPHIPATHIC ENDGROUPS | THE POLYMER TECHNOLOGY GROUP, INC. | 2010-05-06 | — | — | US | disclosed |
| US-7671162-B2 | Control of polymer surface molecular architecture via amphipathic endgroups | DSM IP ASSETS B.V. (NL) | 2010-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071570-A1 | NOVEL ACYL ACIDIC AMINO ACID ESTER | FFAR2, FFAR1, FFAR3 | TSHR 3923/4885MEN1 647/4885THRB 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.